Free Trial 中
Wind ESG Rating

Access to ESG rating for China A-Shares and Hong Kong listed companies.

皓元医药

688131.SH
Wind Industry: 医疗保健 > 医药生物 > 生命科学工具和服务Ⅲ > 生命科学工具和服务Ⅳ

公司成立于2006年，专注于为全球制药和生物医药行业提供小分子、大分子及新分子类型药物发现领域的生命科学试剂的研发，原料药、中间体、起始物料及制剂的药物研发，工艺优化及商业化生产。公司始终将创新作为核心驱动力，以“产品+服务”模式，聚焦差异化发展，致力于打造覆盖药物研发及生产“起始物料-中间体-原料药-制剂”的一体化服务平台，加速赋能全球合作伙伴实现从临床前到商业化生产的全过程，让药物研发更高效，更快上市，更早惠及人类健康。在生命科学试剂业务领域，公司处于国内龙头地位并具备较强的国际影响力。在中间体、特色原料药和制剂业务领域，公司致力于打造客户信赖的全球CRO&CDMO合作伙伴，在ADC早期发现到CDMO比较细分专业领域中，公司处于第一梯队。公司已与多个地区的知名医药企业、科研院所、CRO公司建立了深度合作关系，被评为国家级专精特新“小巨人”企业、国家知识产权优势企业、上海市创新型企业总部、上海市企业技术中心等。未来，公司将持续围绕“产业化、全球化、品牌化”发展战略，坚持“一切为了客户，一切源于创新”的服务宗旨，深耕药物研发服务与产业化，打造具有国际竞争力的、世界一流的医药研发和生产服务企业，推动研发创新以改善全球病患的生存状态和生活质量。

ESG Score Industry Ranking:
5 / 36 (生命科学工具和服务Ⅲ)

ESG Rating Distribution(生命科学工具和服务Ⅲ)

Trend of Rating

2022-08-01: BB; 2023-08-01: BBB; 2024-06-09: BBB; 2025-08-01: AA; 2026-06-24: AA BB2022.08 BBB2023.08 BBB2024.06 AA2025.08 AA2026.06

About Wind ESG Rating

Wind has developed a rigorous rating methodology based on the core connotations of ESG, aligning with international standards and frameworks, and incorporating the characteristics of Chinese companies, to assess the company's essential ESG performance, risk and its ability to operate sustainably.

Focusing on the ESG risks and opportunities of each industry, the companies are rated on a AAA-CCC scale relative to the performance of their industry peers. Wind ESG rating is updated annually or in response to major changes.

The Wind ESG Rating Issuer Communication Platform (esg.wind.com.cn) is now available. Rated companies can access their detailed rating information through this platform, and communicate with or provide feedback to the Wind ESG Rating team regarding specific rating components. For any additional questions, please feel free to send an email to GR.ESG@wind.com.cn.

ESG Score

ESG Score：8.31Updated on 2026-10-29
08.3110
Management & Practices Score：5.31Updated on 2026-10-15
05.317
Controversies Score：2.99Updated on 2026-10-29
02.993

ESG Score Comparison

Environmental Social Governance 皓元医药生命科学工具和服务Ⅲ Average
IndicatorCompany ScoreIndustry AverageWeight
Environmental6.303.7915.43%
Social7.845.1558.35%
Governance7.796.3326.22%

Wind ESG Rating Framework

Building on the foundation of domestic and international ESG policies and standards, our proprietary ESG rating framework considers the development of Chinese capital market and integrates the characteristics of the Chinese companies in various industries. The Wind ESG Rating framework is composed of management & practice and controversies assessment, including:

  • 500+ management & practices indicators, covering E, S and G pillars, reflecting long-term ESG fundamental impacts
  • 1,200+ risk labels, covering news, regulatory penalties and lawsuits, reflecting impact of short-term risks

Management & practice score is the weighted summation of E, S and G pillar scores. The weights reflect both the relative impact of each issue within each industry and the negative or positive contribution of each industry to the environment and society relative to other industries.

Controversies score and ESG score are updated daily, E, S and G pillar scores and management & practice score are updated with underlying data, corresponding data are released on various channels, including Wind Financial Terminal.

Explore More

Wind ESG Rating Methodology.pdf1,198KB Wind ESG Ratings FAQs.pdf755KB
More Details

Peer Comparison(36 companies in the industry) ?

RankingCodeSecurity NameESG RatingESG ScoreControversies ScoreManagement & Practices ScoreEnvironmentalSocialGovernance
1688114.SH华大智造AA8.822.985.856.928.778.25
2300725.SZ药石科技AA8.523.005.528.877.338.55
3002821.SZ凯莱英A8.442.985.476.417.968.30
4301230.SZ泓博医药AA8.332.975.366.798.137.13
5688131.SH皓元医药AA8.312.995.316.307.847.79
6688238.SH和元生物AA8.212.785.434.788.617.58
7688202.SH美迪西AA8.192.975.225.247.937.68
8688222.SH成都先导AA8.112.995.126.027.597.46
9300759.SZ康龙化成AA8.052.935.127.677.436.83
9603259.SH药明康德AA8.052.995.077.746.568.46